Amicus Secures License for DMX-200 Development

Amicus ( (FOLD) ) has provided an announcement.

On April 30, 2025, Amicus Therapeutics entered into a license agreement with Dimerix Bioscience, granting Amicus exclusive rights to develop, manufacture, and commercialize Dimerix’s drug candidate DMX-200 in the United States for Focal Segmental Glomerulosclerosis (FSGS) and other indications. This agreement, effective May 1, 2025, includes a $30 million upfront payment and potential milestone payments totaling up to $560 million. Dimerix will continue funding the ongoing pivotal Phase 3 study for DMX-200, while Amicus will handle regulatory submissions and commercialization in the U.S. This collaboration aims to bring a transformative treatment to patients with FSGS, a rare kidney disease with limited treatment options, enhancing Amicus’s portfolio in the rare disease market.

Spark’s Take on FOLD Stock

According to Spark, TipRanks’ AI Analyst, FOLD is a Neutral.

Amicus Therapeutics shows promising revenue growth and operational improvements but struggles with profitability and high leverage. Technical indicators suggest current downward momentum, though oversold conditions may indicate a potential rebound. Valuation metrics are weak due to negative earnings, but the positive outlook from the earnings call supports future growth prospects.

To see Spark’s full report on FOLD stock, click here.

More about Amicus

Amicus Therapeutics is a global biotechnology company focused on discovering, developing, and delivering novel, high-quality medicines for people living with rare diseases. The company is dedicated to advancing a pipeline of cutting-edge, first- or best-in-class medicines for rare diseases.

YTD Price Performance: -17.51%

Average Trading Volume: 3,114,605

Technical Sentiment Signal: Buy

Current Market Cap: $2.36B

See more insights into FOLD stock on TipRanks’ Stock Analysis page.